Mild Cognitive Impairment
Allan Levey, MD, PhD
This multinational study is using a placebo or the study drug, BAN240, to determine clinical efficacy and to explore the dose response of this drug. BAN2401 is an 18-month study in which drug/placebo is infused biweekly (once every 2 weeks). Subjects will be from 2 clinical subgroups: MCI due to Alzheimer's disease (AD) or mild Alzheimer's disease dementia. Effectiveness of drug treatment will be assessed using cognitive tests, as well as biological markers (MRI, PET, CSF, blood).
For more information about this research study, please call Gail Schwartz at 404-712-6888 or email email@example.com.
Atomoxetine Clinical Trial:
Allan Levey, MD, PhD
Director Emory Alzheimer's Disease Research Center, Chair, Emory University Department of Neurology
The purpose of this study is to find out if atomoxetine causes a change in the biological markers (substances that may indicate the presence of a disease) in the cerebrospinal fluid (CSF) of participants diagnosed with Mild Cognitive Impairment (MCI). In this research study, the spinal fluid of subjects with MCI who take atomoxetine will be compared to spinal fluid of those who take capsules containing inactive material, also known as placebo. At the six-month time point, subjects who were taking placebo during the first six months will be placed on active study medication, and those who received active study medication will be reassigned to placebo. This study will also evaluate if the drug is safe and well-tolerated. Additionally, information will be gathered to identify the dose of atomoxetine that is most beneficial, and how taking this medication affects thinking and behavior, as well as imaging and blood biomarkers.
For more information about this research study, please call Tamara Attis at 404-712-6914 or email firstname.lastname@example.org.
Emory Alzheimer's Disease Research Center Honor Research Registry
James Lah, MD, PhD
Clinical Core Leader, Emory Alzheimer's Disease Research Center
Felicia Goldstein, PhD
Clinical Core Co-Leader, Emory Alzheimer's Disease Research Center
The purpose of Honor is to have a group of volunteers who want to participate in future research studies on memory & thinking. By joining Honor you will learn about new research studies that are seeking volunteers. You will also receive our newsletter and invitations to educational events.
All Honor volunteers must have a “study partner” accompany them to their research visit. Your study partner will be asked questions about your memory and thinking. They will also be asked about your day to day functioning. A study partner is someone who has at least 10 hours of contact with you each week.
For more information about this research study, please call Erin Carter at 404-712-6838 or email email@example.com.
The purpose of this trial is to assess the efficacy and safety of MK-8931 compared with placebo in the treatment of MCI due to AD, also known as prodromal AD. Participants will be randomized to receive placebo, or 12 mg or 40 mg MK-8931, once daily. The primary study hypothesis is that at least one MK-8931 dose is superior to placebo with respect to the change from baseline in the cognitive assessment scores at 104 weeks.
For more information about this research study, please call Phyllis Vaughn at 404-712-6901 or email firstname.lastname@example.org.
This proof-of-concept study is for people with mild cognitive impairment or Alzheimer’s disease. This is a brief study in which participants will be asked to ingest the spice curcumin for 4 days. Curcumin binds to the protein associated with Alzheimer’s disease, and it is possible to visualize it by looking into the eyes. Photographs of the eyes will be taken prior to treatment and after 4 days of ingesting curcumin. The pupils of the eyes will be dilated. Participants must come to the clinic for 2 visits.
For more information about this research study, please call CeeCee Manzanares at 404-727-9324 or email email@example.com.